Search

Your search keyword '"DI CAPUA, Lorena"' showing total 4 results
Start Over Author "DI CAPUA, Lorena"
4 results on '"DI CAPUA, Lorena"'

1. Effetti sull'infiammazione sistemica di approcci nutrizionali utili per la riduzione del rischio cardiovascolare

Author

DI CAPUA, LORENA, BOZZETTO, LUTGARDA, DE NATALE, CLAUDIA, PATTI, LIDIA, MAIONE, SIMONA, STRAZZULLO, ALFONSO, COSTABILE, GIUSEPPINA, RICCARDI, GABRIELE, RIVELLESE, ANGELA ALBAROSA, ANNUZZI, GIOVANNI, Giacco, R., DI CAPUA, Lorena, Bozzetto, Lutgarda, DE NATALE, Claudia, Giacco, R., Patti, Lidia, Maione, Simona, Strazzullo, Alfonso, Costabile, Giuseppina, Riccardi, Gabriele, Rivellese, ANGELA ALBAROSA, and Annuzzi, Giovanni

Subjects
Inflammation, Diabetes mellitu, hs-CRP, Endocrinology, Endocrinology, Diabetes and Metabolism, Internal Medicine, Diet
Published
2010

3. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study.

Author

Detoraki, Aikaterini, Di Capua, Lorena, Varricchi, Gilda, Genovese, Arturo, Marone, Gianni, and Spadaro, Giuseppe

Subjects
*CHURG-Strauss syndrome, *IMMUNOSUPPRESSIVE agents, *FOLLOW-up studies (Medicine), *EOSINOPHILIA, *ASTHMA diagnosis, *PATIENTS, *DIAGNOSIS, *THERAPEUTICS
Abstract

Objective: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis characterized by asthma and blood eosinophilia, with the lung being the organ most frequently affected. Oral glucocorticoids and/or immunosuppressive drugs are the mainstay therapy of EGPA. Occasional reports suggest that EGPA patients can be treated with omalizumab in addition to conventional therapy to achieve asthma control. To investigate the long-term effects of omalizumab in patients with EGPA and asthma (2 females, 3 males, age 41–64 years), we carried out a 36-month follow-up observational study. At the time of enrollment, the patients were on maintenance therapy and had moderate to severe allergic asthma, eosinophilia and rhinosinusitis. Mononeuropathy/polyneuropathy and/or histological evidence of tissue eosinophilic infiltration were also present.Methods: Patients were treated with omalizumab (300–600 mg s.c. every 2–4 weeks) as add-on therapy to prednisone, inhaled steroids and bronchodilators. During omalizumab treatment, spirometry, the asthma control test (ACT) score and eosinophilia were evaluated, and prednisone dosage was recorded.Results: During the 36 months of omalizumab treatment asthma progressively improved as indicated by spirometry and the ACT score. Eosinophilia progressively decreased. The oral prednisone dose was reduced or withdrawn during treatment. No adverse events were recorded.Conclusions: In patients with EGPA and moderate to severe allergic asthma, omalizumab can be beneficial and safe. It enables corticosteroid tapering while decreasing eosinophilia and improving asthma symptoms over 36 months. [ABSTRACT FROM PUBLISHER]

Published
2016
Full Text
View/download PDF

4. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: A 36-month follow-up study

Author

Gianni Marone, Lorena Di Capua, Aikaterini Detoraki, Gilda Varricchi, Arturo Genovese, Giuseppe Spadaro, Detoraki, Aikaterini, Di Capua, Lorena, Varricchi, Gilda, Genovese, Arturo, Marone, Gianni, and Spadaro, Giuseppe

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Omalizumab, 03 medical and health sciences, 0302 clinical medicine, Maintenance therapy, Prednisone, Forced Expiratory Volume, Eosinophilic, Eosinophilia, Case report, medicine, Humans, Immunology and Allergy, Anti-Asthmatic Agents, Morbidity and mortality, Glucocorticoids, Asthma, 030203 arthritis & rheumatology, business.industry, Granulomatosis with Polyangiitis, Middle Aged, medicine.disease, Dermatology, Pharmacotherapy, respiratory tract diseases, Treatment Outcome, 030228 respiratory system, Spirometry, Immunology, Pediatrics, Perinatology and Child Health, Drug Therapy, Combination, Female, Therapy, medicine.symptom, Granulomatosis with polyangiitis, business, Control/management, Systemic vasculitis, medicine.drug
Abstract

Objective: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis characterized by asthma and blood eosinophilia, with the lung being the organ most frequently affected. Oral glucocorticoids and/or immunosuppressive drugs are the mainstay therapy of EGPA. Occasional reports suggest that EGPA patients can be treated with omalizumab in addition to conventional therapy to achieve asthma control. To investigate the long-term effects of omalizumab in patients with EGPA and asthma (2 females, 3 males, age 41-64 years), we carried out a 36-month follow-up observational study. At the time of enrollment, the patients were on maintenance therapy and had moderate to severe allergic asthma, eosinophilia and rhinosinusitis. Mononeuropathy/polyneuropathy and/or histological evidence of tissue eosinophilic infiltration were also present. Methods: Patients were treated with omalizumab (300-600 mg s.c. every 2-4 weeks) as add-on therapy to prednisone, inhaled steroids and bronchodilators. During omalizumab treatment, spirometry, the asthma control test (ACT) score and eosinophilia were evaluated, and prednisone dosage was recorded. Results: During the 36 months of omalizumab treatment asthma progressively improved as indicated by spirometry and the ACT score. Eosinophilia progressively decreased. The oral prednisone dose was reduced or withdrawn during treatment. No adverse events were recorded. Conclusions: In patients with EGPA and moderate to severe allergic asthma, omalizumab can be beneficial and safe. It enables corticosteroid tapering while decreasing eosinophilia and improving asthma symptoms over 36 months.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results